Aug 2, 2022 4:15 pm EDT Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022
Jul 27, 2022 8:00 am EDT Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia
Jun 14, 2022 8:00 am EDT Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101
May 23, 2022 4:15 pm EDT Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program
May 18, 2022 7:30 am EDT Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints
May 16, 2022 1:30 pm EDT Acasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 18th
Apr 25, 2022 8:30 am EDT Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th